The OncoMasTR gene expression profiling test for early-stage breast cancer prognosis
was first discovered via a novel transcriptional network analysis approach,
which identified upstream Master Transcriptional Regulators (MTRs)
of three independent breast cancer prognosis signatures1,2.
The test has been analytically and clinically validated for use as a decentralised kit
and the signature was shown to be significantly prognostic for distant recurrence for ER-positive,
HER2-negative early stage breast cancer with up to three involved lymph nodes3.
OncoMark is an Irish-based diagnostic company focused on the development of novel panels of cancer biomarkers
to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life
for cancer patients.